肝静脉侵犯的肝细胞癌肝切除术:日本全国性调查
基于日本全国性调查数据,分析2000至2007年间登记的1021例无下腔静脉侵犯的Child-Pugh A级肝细胞癌合并肝静脉癌栓患者,比较540例肝切除与481例其他治疗。倾向评分匹配后肝切除组中位生存期较非肝切除组延长(4.47年 vs 1.58年,P<0.001;匹配队列3.42年 vs 1.81年,P=0.023)。结论认为肝切除与良好预后相关,尤其在无门静脉癌栓患者中。
要点
- 肝切除组中位生存期4.47年,非肝切除组1.58年(P<0.001)。
- 倾向评分匹配队列中肝切除组3.42年,非肝切除组1.81年(P=0.023)。
- 无门静脉癌栓患者中位生存期5.67年,优于有门静脉癌栓者1.88年(P<0.001)。
核心结论
- 肝切除与肝细胞癌合并肝静脉癌栓患者的良好预后相关,尤其在无门静脉癌栓的患者中。
研究设计与样本
- 日本全国性调查分析,纳入2000至2007年间登记的1021例无下腔静脉侵犯的Child-Pugh A级肝细胞癌合并肝静脉癌栓患者,其中540例接受肝切除,481例接受其他治疗。
- 采用倾向评分匹配,成功匹配223例(占肝切除组的49.0%)。
主要发现
- 肝切除组中位生存期较非肝切除组延长2.89年(4.47年 vs 1.58年,P<0.001)。
- 倾向评分匹配队列中肝切除组中位生存期较非肝切除组延长1.61年(3.42年 vs 1.81年,P=0.023)。
- 根治性切除后,外周肝静脉癌栓患者与主要肝静脉癌栓患者的中位生存期相似(4.85年 vs 4.67年,P=0.974)。
- 肝切除组术后90天死亡率为3.4%(16例)。
- 无门静脉癌栓患者中位生存期显著优于有门静脉癌栓患者(5.67年 vs 1.88年,P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Because of the rarity of hepatic vein tumor thrombus (HVTT) compared with portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma, little is known about this disease entity. The aim of this study was to evaluate the prognosis of each treatment modality for HVTT through an analysis of data collected in a Japanese nationwide survey. We analyzed data for 1,021 Child-Pugh A hepatocellular carcinoma patients with HVTT without inferior vena cava invasion registered between 2000 and 2007. Of these patients, 540 who underwent liver resection (LR) and 481 who received other treatments were compared. Propensity scores were calculated, and we successfully matched 223 patients (49.0% of the LR group). The median survival time in the LR group was 2.89 years longer than that in the non-LR group (4.47 versus 1.58 years, P < 0.001) and 1.61 years longer than that in the non-LR group (3.42 versus 1.81 years, P = 0.023) in a propensity score-matched cohort. After curative resection, median survival times were similar between patients with HVTT in the peripheral hepatic vein and those with HVTT in the major hepatic vein (4.85 versus 4.67 years, P = 0.974). In the LR group, the postoperative 90-day mortality rate was 3.4% (16 patients). In patients without PVTT, the median survival time was significantly better than that in patients with PVTT (5.67 versus 1.88 years, P < 0.001). CONCLUSION: LR is associated with a good prognosis in hepatocellular carcinoma patients with HVTT, especially in patients without PVTT. (Hepatology 2017;66:510-517).
引用
- Kokudo T, Hasegawa K, Matsuyama Y, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. Hepatology. 2017. PMID: 28437844. doi:10.1002/hep.29225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。